Introduction: Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC) has shown superior penetration depth and tissue uptake compared to standard PIPAC. We investigated the feasibility and objective tumor response to ePIPAC with 1 min of precipitation in patients with peritoneal metastasis (PM).
Materials and methods: Patients with PM from various abdominal cancers were included in an amendment to the ongoing prospective PIPAC-OPC2 trial. Colorectal and appendiceal PM were treated with oxaliplatin, patients with PM from other primaries were treated with a combination of cisplatin and doxorubicin. Three ePIPAC procedures were planned in each patient including repeated peritoneal biopsies for response evaluation. After emission to the peritoneal cavity, the aerosolized chemotherapeutics were precipitated for 1 min followed by immediate exsufflation and abdominal closure. Histological regression from the first to the third ePIPAC was evaluated according to the Peritoneal Regression Grading Score (PRGS) and compared to data from the PIPAC-OPC1 trial. Complications and toxicities were recorded according to Dindo-Clavien and CTCAE.
Results: Sixty-five ePIPAC procedures were performed in 33 patients (median 2, range 1-6). Ten patients were eligible for response evaluation based on biopsies from the first and third ePIPAC procedure. Four patients had disease progression, four patients had regressive disease, and two patients had stable disease according to PRGS. No life threatening adverse reactions and no mortality was observed following ePIPAC.
Conclusion: One minute ePIPAC was feasible and safe, but the histological tumor response was insufficient compared to standard PIPAC directed therapy with 30 min passive diffusion time.
Keywords: Feasibility; Intraperitoneal chemotherapy; PIPAC; Peritoneal metastasis; Tumor response; ePIPAC.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application.Pleura Peritoneum. 2016 Jun 1;1(2):109-116. doi: 10.1515/pp-2016-0005. Epub 2016 Apr 29. Pleura Peritoneum. 2016. PMID: 30911614 Free PMC article.
In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC).Ann Surg Oncol. 2016 Dec;23(Suppl 5):592-598. doi: 10.1245/s10434-016-5108-4. Epub 2016 Feb 2. Ann Surg Oncol. 2016. PMID: 26842487 Free PMC article.
Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).BMJ Open. 2019 Jul 27;9(7):e030408. doi: 10.1136/bmjopen-2019-030408. BMJ Open. 2019. PMID: 31352425 Free PMC article.
Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey.Clin Exp Metastasis. 2018 Mar;35(3):103-108. doi: 10.1007/s10585-018-9895-9. Epub 2018 Apr 28. Clin Exp Metastasis. 2018. PMID: 29705882 Review.
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Eur J Surg Oncol. 2019 Jun 21:S0748-7983(19)30522-0. doi: 10.1016/j.ejso.2019.06.028. Online ahead of print. Eur J Surg Oncol. 2019. PMID: 31253545 Review.
Cited by 2 articles
Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) after High-Intensity Ultrasound (HIUS).Int J Surg Oncol. 2019 Dec 12;2019:6185313. doi: 10.1155/2019/6185313. eCollection 2019. Int J Surg Oncol. 2019. PMID: 31915548 Free PMC article.
Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).Cancers (Basel). 2019 Dec 20;12(1):34. doi: 10.3390/cancers12010034. Cancers (Basel). 2019. PMID: 31877647 Free PMC article. Review.